Revolutionizing Eye Care with AI

In the ever-evolving landscape of healthcare, technology continues to transform the way medical care is delivered. Artificial Intelligence (AI) is reshaping possibilities for medical screening and treatment, bringing groundbreaking advancements to eye care.

Globally, over 2.2 billion people suffer from vision impairment or blindness, nearly half of which are preventable or treatable. The burden is particularly severe in low-resource settings, where access to specialized care is limited. Traditional diagnostic methods often require expensive equipment, skilled professionals, and significant time investments—barriers that hinder early detection and effective screening.

Addressing this challenge demands a paradigm shift in healthcare delivery. Remidio is leading this transformation with its cutting-edge technology and AI-driven solutions, bridging gaps in care and revolutionizing screening processes worldwide.

Remidio Innovative Solutions Pvt. Ltd., headquartered in Bengaluru, India, introduced the world’s first portable, handheld, smartphone-based non-mydriatic fundus camera: the Fundus-on-Phone (FOP) NM-10. This groundbreaking device captures high-quality retinal images without the need for pupil dilation, addressing critical barriers to eye care.

The FOP NM-10’s portability and affordability enable its use in remote and underserved areas, where traditional equipment and specialists may not be available. Currently utilized by medical specialists, such as ophthalmologists, diabetologists, and general physicians, as well as by non-medical personnel, this innovation ensures that quality eye care reaches even the most marginalized communities.

In 2019, Remidio achieved a significant milestone by developing an offline AI solution called Remidio’s Medios AI, which operates without the need for internet connectivity. This advanced technology integrates AI with fundus cameras to analyze retinal images and detect abnormalities, effectively screening for major sight-threatening conditions.

The widening gap in access to quality eye care has brought AI to the forefront of vision care. AI’s ability to quickly and accurately analyze large datasets has driven significant innovations in screening and diagnostics. By predicting, detecting, and monitoring conditions early, AI-powered tools enable timely interventions, improve treatment outcomes, and enhance overall healthcare efficiency.

Remidio’s Medios AI addresses critical healthcare challenges by identifying individuals at risk for diabetic retinopathy, glaucoma, and age-related macular degeneration (AMD) using retinal images. To ensure the accuracy and reliability of its AI predictions and recommendations, Remidio implemented several rigorous measures during the development and validation phases. The AI was trained on diverse datasets representing various ethnicities, populations, and genders to ensure broad applicability and minimize biases. Ground truth data was meticulously validated by clinicians to guarantee precision.

Following its development, the AI underwent extensive real-world testing in environments such as tertiary eye care centers, vision centers, community screening programs, and diabetologist clinics. Additionally, it was evaluated across diverse populations and ethnicities to confirm its effectiveness and reliability.

Remidio has deployed over 3,500 AI-powered fundus cameras, including the FOP NM-10, across 43 countries, positively impacting more than 10 million lives globally. A significant milestone was achieved in India, where the device has been deployed as part of large-scale public health initiatives. Remidio has deployed over 4,000 devices, impacting 10 million lives across 43 countries, including the US, where it is the market #2 provider of portable retinal cameras, with 1,000 devices innovated in India now being used by healthcare professionals in the US. This global success highlights the scalability and effectiveness of Remidio’s innovations.

In Kerala, the Nayanamritam program began in 2019 with 16 centers and has now expanded to over 210 centers, aiming to screen 1.3 million individuals annually for diabetic retinopathy and other vision-threatening conditions.

In Tamil Nadu, more than 80 healthcare facilities use the device, while in Odisha, the government has placed devices in over 30 district and sub-district hospitals, enhancing eye care accessibility for underserved populations.

Collaborations with leading institutions, including AIIMS New Delhi, Aravind Eye Care System (25+ vision centers), Sankara Eye Foundation (40+ vision centers), and Dr. Shroff’s Charity Eye Hospital, have further extended the device’s impact. These partnerships empower ophthalmologists and mid-level personnel to conduct screenings, triage cases, and optimize specialist schedules, improving efficiency and outcomes in resource-constrained settings.

The FOP NM-10 has also made its mark globally, with partnerships such as the NHS in the UK, validating its efficacy for large-scale screening programs. Its scalability ensures it can deliver quality care to diverse populations, reducing the burden on tertiary care facilities while improving health outcomes.

Remidio prioritizes data privacy and security, especially when handling sensitive health information. During operation, no data is fed into the AI, and the technology was developed in strict adherence to ethical guidelines. All patient identifiers, including age, gender, and ethnicity, were removed prior to data processing. Furthermore, Remidio’s devices comply with global standards such as the Health Insurance Portability and Accountability Act (HIPAA) and the General Data Protection Regulation (GDPR), ensuring robust data privacy and security.

As Remidio expands its solutions to over 45 countries, its clinical and AI research team, led by an ophthalmologist, is exploring new frontiers. The human eye offers a unique, non-invasive window into the body's vascular and nervous systems, making it an invaluable tool for detecting systemic diseases such as cardiovascular and neurodegenerative conditions.

Remidio’s mission is to empower healthcare providers with accessible, integrated solutions that enable early diagnosis and intervention. By extending screening capabilities to the most remote locations, Remidio aims to reduce avoidable blindness, improve health outcomes, and enhance the quality of life for millions.

At Remidio, the vision is clear: a world where everyone has the right to sight. By combining technological innovation with a commitment to patient care, Remidio is addressing one of the most pressing global health challenges. This journey is about more than just technology—it is about revolutionizing healthcare with empathy and creating a lasting impact.